Rodríguez RH, Samada SM, Hernández PJC, Pérez GT, Cruz HZD, Barroso ML

Language: Spanish
References: 22
Page: 214-228
PDF size: 413.79 Kb.

ABSTRACT

Introduction: The liver diseases of autoimmune etiology are cause of chronic hepatopathies able to progress to the cirrhosis in dependency of the stage to the moment of the diagnostic and of the answer or no to the treatment. Methods: It realized a descriptive study, retrospective and prospective, with the aim to define the clinical and demographic characteristics of the patients with autoimmune hepatic illnesses attended in the outpatient of Hepatology at CIMEQ, between November of the 2010 and June of the 2013. Results: Of 46 patients studied the most frequent entity was the Autoimmune Hepatitis (59 %) gone on down the Overlap Syndrome (17 %). The 66.7 % of the patients presented compensated cirrhosis to the moment of the diagnostic of Autoimmune Hepatitis and of the 50 % of which had Primary Biliary Cirrhosis. The 80 % of the patients with Primary Sclerosing Cholangitis and the 37.5 % of which had overlap syndrome presented compensated cirrhosis. Conclusions: It predominated the female and the fourth decade of the life in the cases diagnosed. The most frequent etiology was the autoimmune hepatitis and more than half of the patients found in stage of compensated cirrhosis to the moment of the diagnostic. In the final evaluation all the etiologic groups had patients with compensated liver cirrhosis.

REFERENCES

1. 1- Parés A. Anticuerpos antitisulares en el diagnóstico de las enfermedades hepáticas autoinmunes. Barcelona, España. Gastroenterol Hepatol. 2008;8(2):7-16.

2. 2- Rodrigo R. Hepatitis autoinmune. En: Berenguer J editor. Gastroenterología y Hepatología. Tercera Edición; Editora Elselvier Science. Barcelona; 2002. p. 630-7.

3. 3- Chaparro M, Moreno JA, García LC, Moreno R. Enfermedades colestásicas crónicas Servicio de Aparato Digestivo. Hospital Universitario de La Princesa. Madrid. Medicine. 2008;10(12):777-83.

4. 4- Invernizzi P, Lleo A, Podda A. Interpreting Serological Test Diagnosing Autoinmune Liver Diseases. Sem Liv Dis. 2007;27:161-72.

5. 5- Gleeson D, Heneghan M. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.

6. 6- Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G,Vergani D, et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Prevención de efectos adversos. Hepatology. 2010;51(2):193-213.

7. 7-Fallalak H, Akbar H, Qari Y. Autoimmune hepatitis: Single center experience of clinical presentation response to treatment and prognosis in Saudi Arabia. Saudi Gastro. 2010;16(2):95-9.

8. 8- Morales G, Zavala C. Colangitis esclerosante primaria. Rev Médica Sur Méx. 2004;8(2):234-6.

9. 9- Orellana I, Valera JM, Nei C, Poniachik J, Berger Z, Latorre R. Colangitis esclerosante primaria: revisión de 12 años en dos centros de referencia. Rev Méd Chile. 2005;133:776-80.

10. 10- Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterol. 2010;139:58-72.

11. 11- Morillas RM, Planas R. Hepatitis autoinmune. En: Montoro MA, García JC editores. Problemas comunes en la práctica clínica. 2da edición; Edita Asociación Española para el Estudio del Hígado. Madrid, España; 2012. p. 747-57.

12. 12- Tejedor M, Martín RM, Martínez J, Albillos A. Avances en la etiopatogenia, diagnóstico y tratamiento de la hepatitis autoinmune. Medic. 2012;11(9):541-8.

13. 13- Parés A. Presentation and natural history of primary biliary cirrhosis in Spain: experience over 35 years. J Hepatol. 2008;35(2):287-90.

14. 14- Parés A. Historia natural de la cirrosis biliar primaria. Barcelona, España. Gastroenterol Hepatol. 2008;31(8):500-7. 15- Czaja AJ. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. Journ Hepatol. 2012;56(5):1181-8.

15. 16- Parés A, Rodés J. Cirrosis biliar primaria. Otras causas de colestasis crónica en el adulto. En: Berenguer J editor. Gastroenterología y Hepatología. Tercera Edición; Editora Elselvier Science. Barcelona; 2002. p. 674-9.

16. 17- Parés A. Colangitis esclerosante primaria: diagnóstico, pronóstico y 22tratamiento. Gastroenterol Hepatol. 2011;34(1):41-52.

17. 18- Pons F, Crespo J. Colangitis esclerosante primaria. En: Berenguer J, Bruguera M, García M, Rodrigo L, editores. Tratamiento de las enfermedades hepáticas y biliares. Edita Asociación Española para el Estudio del Hígado. Madrid, España; 2001. p. 229-37.

18. 19- Morales G, Zavala C. Colangitis esclerosante primaria. Rev Médica Sur Méx. 2004;8(2):240-2.

19. 20- Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, et al. Autoimmune Hepatitis – PBC Overlap Syndrome:A Simplifi ed Scoring System May Assist in the Diagnosis. Am J Gastroenterol. 2010;105:345-53.

20. 21- Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med. 2007;357(15):1524-9.

21. 22- Fevery J, Verslype C, Lai G, Aerts R, Van SW. Incidence, diagnosis,and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123-35.

22. 23- Mallo N, López R, Campos J. Síndrome over lap hepatitis autoinmune-cirrosis biliar primaria: a propósito de un caso. Santiago de Compostela, España. An Med Interna. 2008;25(3):122-4.